journal
MENU ▼
Read by QxMD icon Read
search

Lancet Haematology

journal
https://www.readbyqxmd.com/read/29150391/diagnosing-pulmonary-embolism-we-are-not-so-different-after-all%C3%A2
#1
Christopher Kabrhel
No abstract text is available yet for this article.
November 14, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29150390/pulmonary-embolism-rule-out-criteria-perc-rule-in-european-patients-with-low-implicit-clinical-probability-percepic-a-multicentre-prospective-observational-study
#2
Andrea Penaloza, Caroline Soulié, Thomas Moumneh, Quentin Delmez, Alexandre Ghuysen, Dominique El Kouri, Christian Brice, Nicolas S Marjanovic, Jacques Bouget, Fares Moustafa, Albert Trinh-Duc, Catherine Le Gall, Lionel Imsaad, Jean-Marie Chrétien, Béatrice Gable, Philippe Girard, Olivier Sanchez, Jeannot Schmidt, Grégoire Le Gal, Guy Meyer, Nicolas Delvau, Pierre-Marie Roy
BACKGROUND: The ability of the pulmonary embolism rule-out criteria (PERC) to exclude pulmonary embolism without further testing remains debated outside the USA, especially in the population with suspected pulmonary embolism who have a high prevalence of the condition. Our main objective was to prospectively assess the predictive value of negative PERC to rule out pulmonary embolism among European patients with low implicit clinical probability. METHODS: We did a multicentre, prospective, observational study in 12 emergency departments in France and Belgium...
November 14, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29146225/response-comparison-of-multiple-myeloma-and-monoclonal-gammopathy-of-undetermined-significance-to-the-same-anti-myeloma-therapy-a-retrospective-cohort-study
#3
John P Campbell, Jennifer L J Heaney, Sankalp Pandya, Zaheer Afzal, Martin Kaiser, Roger Owen, J Anthony Child, David A Cairns, Walter Gregory, Gareth J Morgan, Graham H Jackson, Chris M Bunce, Mark T Drayson
BACKGROUND: Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-multiple myeloma therapy if it is causing substantial disease through deposition of secreted M proteins. However, studies comparing how MGUS and multiple myeloma plasma cell clones respond to these therapies are scarce. Biclonal gammopathy multiple myeloma is characterised by the coexistence of an active multiple myeloma clone and a benign MGUS clone, and thus provides a unique model to assess the responses of separate clones to the same anti-multiple myeloma therapy, in the same patient, at the same time...
November 13, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29054816/an-alternative-to-radiotherapy-in-consolidation-of-brain-lymphoma
#4
David Schiff
No abstract text is available yet for this article.
October 17, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29054815/whole-brain-radiotherapy-or-autologous-stem-cell-transplantation-as-consolidation-strategies-after-high-dose-methotrexate-based-chemoimmunotherapy-in-patients-with-primary-cns-lymphoma-results-of-the-second-randomisation-of-the-international-extranodal-lymphoma
#5
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, Alberto Fabbri, Valter Torri, Eleonora Minacapelli, Monica Falautano, Fiorella Ilariucci, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Peter Johnson, Kim M Linton, Tobias Pukrop, Jette Sønderskov Gørløv, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jens Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Alessandro Levis, Stefan W Krause, Hans J Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, Francesco Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested...
October 17, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29021124/finally-what-we-have-been-waiting-for-evidence-that-transfusion-of-rbcs-at-the-extreme-of-the-storage-spectrum-is-safe
#6
Eric A Gehrie, Aaron A R Tobian
No abstract text is available yet for this article.
October 5, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29021123/red-blood-cell-storage-and-in-hospital-mortality-a-secondary-analysis-of-the-inform-randomised-controlled-trial
#7
Richard J Cook, Nancy M Heddle, Ker-Ai Lee, Donald M Arnold, Mark A Crowther, Philip J Devereaux, Martin Ellis, Priscilla Figueroa, Andrea Kurz, David Roxby, Daniel I Sessler, Yehudit Sharon, Magdalena Sobieraj-Teague, Theodore E Warkentin, Kathryn E Webert, Rebecca Barty, Yang Liu, John W Eikelboom
BACKGROUND: No randomised trials have addressed whether exposure to red blood cells (RBCs) stored longer than 35 days is associated with harm in patients. We aimed to assess the risk of in-hospital mortality associated with transfusing blood stored longer than 35 days. METHODS: We did a secondary analysis of the INforming Fresh versus Old Red cell Management (INFORM) trial, a pragmatic, multicentre, randomised controlled trial of patients (≥18 years) admitted to one of six hospitals in Australia, Canada, Israel, and the USA and expected to need RBC transfusions...
October 5, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28916312/lenalidomide-maintenance-in-high-risk-chronic-lymphocytic-leukaemia-practice-changing-study-or-hypothesis-generating-approach
#8
Davide Rossi, Adalgisa Condoluci
No abstract text is available yet for this article.
September 12, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28919085/blood-transfusion-strategies-in-elderly-patients
#9
Michael F Murphy, Lise Estcourt, Lawrence Tim Goodnough
No abstract text is available yet for this article.
September 11, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29100558/immunohaematological-complications-in-patients-with-sickle-cell-disease-after-haemopoietic-progenitor-cell-transplantation-a-prospective-single-centre-observational-study
#10
Elizabeth S Allen, Kshitij Srivastava, Matthew M Hsieh, Courtney D Fitzhugh, Harvey G Klein, John F Tisdale, Willy A Flegel
BACKGROUND: Haemopoietic progenitor cell (HPC) transplantation can cure sickle cell disease. Non-myeloablative conditioning typically results in donor-derived erythrocytes and stable mixed chimerism of recipient-derived and donor-derived leucocytes. Exposure to donor antigens from the HPC graft and new red cell antibodies induced by transfusion can lead to immunohaematological complications. We assessed the incidence of such complications among HPC transplant recipients with sickle cell disease...
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29100557/authors-reply-to-comment-what-should-be-the-endpoints-of-a-symptomatic-drug-and-its-control
#11
LETTER
Ruben Mesa, Claire Harrison
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29100556/red-blood-cell-alloimmunisation-in-patients-with-sickle-cell-disease
#12
Fernanda Volt
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29100555/keeping-the-blood-flowing-during-times-of-disaster
#13
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29032958/treatment-of-iron-deficiency-is-getting-trendy
#14
Michael Auerbach, Stanley Schrier
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29032957/iron-absorption-from-oral-iron-supplements-given-on-consecutive-versus-alternate-days-and-as-single-morning-doses-versus-twice-daily-split-dosing-in-iron-depleted-women-two-open-label-randomised-controlled-trials
#15
Nicole U Stoffel, Colin I Cercamondi, Gary Brittenham, Christophe Zeder, Anneke J Geurts-Moespot, Dorine W Swinkels, Diego Moretti, Michael B Zimmermann
BACKGROUND: Current guidelines to treat iron deficiency recommend daily provision of ferrous iron divided through the day to increase absorption. However, daily dosing and split dosing might increase serum hepcidin and decrease iron absorption from subsequent doses. Our study aim was to compare iron absorption from oral iron supplements given on consecutive versus alternate days and given as single morning doses versus twice-daily split dosing. METHODS: We did two prospective, open-label, randomised controlled trials assessing iron absorption using ((54)Fe)-labelled, ((57)Fe)-labelled, or ((58)Fe)-labelled ferrous sulfate in iron-depleted (serum ferritin ≤25 μg/L) women aged 18-40 years recruited from ETH Zurich and the University of Zurich, Switzerland...
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28958469/lenalidomide-maintenance-therapy-in-previously-treated-chronic-lymphocytic-leukaemia-continuum-a-randomised-double-blind-placebo-controlled-phase-3-trial
#16
Asher A Chanan-Khan, Andrey Zaritskey, Miklos Egyed, Samuel Vokurka, Sergey Semochkin, Anna Schuh, Jeannine Kassis, David Simpson, Jennie Zhang, Brendan Purse, Robin Foà
BACKGROUND: The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and refractory disease, not all patients have access to these novel drugs. In this study, we aimed to assess the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated chronic lymphocytic leukaemia...
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28958468/maintenance-lenalidomide-could-be-most-relevant-after-first-line-therapy
#17
Julie E Chang
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28919086/authors-reply-to-comment-blood-transfusion-strategies-in-elderly-patients
#18
LETTER
Geoff I Simon, Alison Craswell, Ogilvie Thom, Yoke Lin Fung
No abstract text is available yet for this article.
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28962681/erythropoietin-on-cycling-performance-authors-reply
#19
LETTER
Jules A A C Heuberger, Joris I Rotmans, Pim Gal, Frederik E Stuurman, Johannes M A Daniels, Marieke L de Kam, Adam F Cohen
No abstract text is available yet for this article.
October 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28962680/erythropoietin-on-cycling-performance
#20
LETTER
Billy Sperlich, José A L Calbet, Hans-Christer Holmberg
No abstract text is available yet for this article.
October 2017: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"